Abstract Details

Title Real-world Acute Treatment Optimization for Migraine with Ubrogepant: Results from the COURAGE II Study

Topic Headache

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 15-015

Objective

To evaluate real-world optimization of ubrogepant for the acute treatment of migraine when given to participants also taking atogepant using the migraine Treatment Optimization Questionnaire (mTOQ).

Background Ubrogepant and atogepant are small-molecule calcitonin gene–related peptide receptor antagonists approved for the acute (ubrogepant) and the preventive (atogepant) treatment of migraine. The COmbining UbRogepAnt and preventives for miGrainE (COURAGE) II study evaluated the real-world effectiveness of ubrogepant in people with migraine also taking atogepant for migraine prevention. Prior reports summarize responses to treated attacks. This report focuses on responses to the 6-Item mTOQ.

Design/Methods

COURAGE II, a prospective, real-world observational study, enrolled participants aged ≥18 years who self-reported a physician diagnosis of migraine, were being treated concomitantly with atogepant and ubrogepant, and were using the Migraine Buddy application to track migraine activity, medication use, and treatment response. At 30 days, a final electronic questionnaire included the 6-Item migraine Treatment Optimization Questionnaire (mTOQ).

Results A total of 352 participants (mean age, 40.7 years) recorded 1614 attacks that were treated with ubrogepant and completed the mTOQ. Based on mTOQ, 67.3% of participants reported quickly returning to normal activity half the time or more; 50.6% reported being pain free half the time or more within 2 hours of taking ubrogepant, and 52.3% reported experiencing pain relief with 1 dose of ubrogepant lasting ≥24 hours half the time or more. Furthermore, 76.4% of participants reported being comfortable enough with ubrogepant to plan daily activities half the time or more. Safety outcomes were consistent with established safety profiles of ubrogepant and atogepant.

Conclusions

When used with atogepant, acute treatment with ubrogepant over multiple attacks for 30 days was associated with favorable acute treatment optimization, including rapid, sustained pain relief with a single dose, enabling resumption and planning of normal daily activity.

Authors/Disclosures
Stephanie J. Nahas, MD, FAAN (Thomas Jefferson University) PRESENTER	Dr. Nahas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for AbbVie. Dr. Nahas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Nahas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Nahas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch Health. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Nahas has received publishing royalties from a publication relating to health care. Dr. Nahas has received publishing royalties from a publication relating to health care. Dr. Nahas has received personal compensation in the range of $500-$4,999 for serving as a expert for CME activities with Medscape/WebMD. Dr. Nahas has a non-compensated relationship as a Board Member-at-Large with American Headache Society that is relevant to AAN interests or activities. Dr. Nahas has a non-compensated relationship as a Executive Board Member with The Headache Alliance that is relevant to AAN interests or activities.
Brittany Mays, MD (Mass General Brigham)	Dr. Mays has nothing to disclose.
Nicole Naccara (Abbvie)	Dr. Naccara has received personal compensation for serving as an employee of Abbvie . Dr. Naccara has stock in Abbvie.
Yicun Wang, PhD	Dr. Wang has nothing to disclose.
Janette Contreras-De Lama	Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��